COLUMBIA, MD., June 04, 2018 (GLOBE NEWSWIRE) -- VAYA™ Pharma, Inc. (VAYA™), a division of Frutarom, Industries Ltd. (LSE:FRUT) (TASE:FRUT) and a leader in specialty nutrition and medical food products, today introduced Vayarin® Plus to its medical food product offerings. Vayarin® Plus, a medical food for the dietary management of attention-deficit/hyperactivity disorder (ADHD) is formulated to help adults and adolescents who have difficulties with attention and components of executive function. Vayarin® Plus is available through a physician prescription as well as online through VAYA Direct.
"Since the launch of Vayarin® in 2011, we have been improving the lives of many young children with ADHD. Now, following the successful completion of our clinical trial, we are excited to offer Vayarin® Plus to help improve the lives of adults and adolescents, giving them a new, efficacious and safe non-drug option to manage their ADHD," said Michelle Cuccia, CEO of VAYA™. “Adult ADHD is a prevalent behavioral disorder that can lead to serious social and professional challenges for patients, and as a rapidly growing segment, there is a significant need for effective and safe non-drug options. People of all ages who are diagnosed with ADHD can benefit from using Vayarin® and Vayarin® Plus to manage their ADHD across different life stages."
Vayarin® Plus
Vayarin® Plus, a new extra-strength formula in the Vayarin® product family, is indicated for the clinical dietary management of ADHD in adults and adolescents over the age of 14 that weigh more than 97 lbs. (44 kilograms). The patent-protected lipid composition in Vayarin® Plus is Generally Recognized as Safe (GRAS). The product is available in a hard-shell capsule, which can be opened and sprinkled on food if desired. The recommended daily dose of Vayarin® Plus is 450 mg of Lipirinen®, provided within two capsules taken once per day. Vayarin® Plus is available in 1-month supply bottles through your local pharmacy, and in 1-month and 3-month bottles through VAYA at www.vayadirect.com.
Vayarin® Plus is a line extension of VAYA’s flagship product Vayarin®, a medical food for the dietary management of ADHD in children 6-13 years of age that has been available in the U.S. since 2011. The active ingredient in Vayarin® and Vayarin® Plus is Lipirinen®, which is a proprietary composition containing phosphatidylserine (PS) conjugated to omega-3 fatty acids enriched with Eicosapentaenoic acid (EPA). The scientific literature establishes a correlation between lipid deficiency and ADHD. Vayarin® Plus compensates for and manages these imbalances and was clinically shown to reduce ADHD behaviors in adults both safely and effectively, while providing all day coverage. VAYA’s medical food products are intended for use under medical supervision.
Vayarin® Plus Clinical Evidence
Vayarin Plus was studied in a multi-center, double-blind, placebo-controlled clinical trial of 189 participants with ADHD aged 18-60, and was shown to effectively and safely improve ADHD behaviors. Dr. Jeffrey Newcorn, Professor of Psychiatry and Pediatrics, and Director of the Division of ADHD and Learning Disorders at Mount Sinai Medical Center in New York, and clinical investigator presented the findings at the International ADHD Congress held in Tel Aviv, Israel in March 2018.
For more information about Vayarin® Plus please visit www.vayadirect.com.
VAYA™ Pharma
VAYA™ Pharma, a division of Frutarom, Industries Ltd. (LSE:FRUT) (TASE:FRUT), is the innovator of lipid-based medical foods that are used to manage distinct nutritional deficiencies associated with certain diseases and health conditions, including Attention Deficit Hyperactivity Disorder (ADHD) and Early Memory Impairment (EMI). Committed to safety and efficacy, VAYA™ Pharma’s innovations – Vayarin®, Vayarin® Plus and Vayacog® – are backed by years of clinical research. VAYA™ Pharma is headquartered in Columbia, Maryland.
For more information about VAYA™ Pharma please visit www.vayapharma.com.
VAYA™ Pharma
Shervin Esfahani
443.995.4299
ShervinE@vayapharma.com